Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.
Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team. Waubant E, et al. Among authors: cross a. Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28. Neurology. 2012. PMID: 22459680 Free PMC article. Clinical Trial.
MS and the B cell controversy.
Cross AH, Waubant E. Cross AH, et al. Biochim Biophys Acta. 2011 Feb;1812(2):231-8. doi: 10.1016/j.bbadis.2010.07.020. Epub 2010 Jul 30. Biochim Biophys Acta. 2011. PMID: 20674743 Free article. Review.
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.
Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E. Greenberg BM, et al. Among authors: cross a. JAMA Neurol. 2013 Feb;70(2):248-51. doi: 10.1001/jamaneurol.2013.1017. JAMA Neurol. 2013. PMID: 23530268 No abstract available.
MS and related disorders: groundbreaking news.
Waubant E, Cross A. Waubant E, et al. Among authors: cross a. Lancet Neurol. 2014 Jan;13(1):11-3. doi: 10.1016/S1474-4422(13)70284-9. Lancet Neurol. 2014. PMID: 24331785 Review. No abstract available.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. Among authors: cross ah. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Cell-based therapeutic strategies for multiple sclerosis.
Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis. Scolding NJ, et al. Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Brain. 2017. PMID: 29053779 Free PMC article. Review.
Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion.
Shirani A, Stuve O, Cross AH. Shirani A, et al. Among authors: cross ah. Neurol Clin. 2024 Feb;42(1):137-153. doi: 10.1016/j.ncl.2023.06.001. Epub 2023 Jul 23. Neurol Clin. 2024. PMID: 37980111 Review.
Anti-CD20 agents do not fully protect from nonrelapsing disease progression, possibly due to their inability to cross the blood-brain barrier and inability to ameliorate the full extent of biology of MS progression. Anti-CD20 mAbs have a relatively favorable safety …
Anti-CD20 agents do not fully protect from nonrelapsing disease progression, possibly due to their inability to cross the blood-brain …
1,830 results